CONMED Management

Management criteria checks 3/4

CONMED's CEO is Curt Hartman, appointed in Jul 2014, has a tenure of 10.33 years. total yearly compensation is $7.76M, comprised of 12.2% salary and 87.8% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth MX$135.58M. The average tenure of the management team and the board of directors is 5.8 years and 9.3 years respectively.

Key information

Curt Hartman

Chief executive officer

US$7.8m

Total compensation

CEO salary percentage	12.2%
CEO tenure	10.3yrs
CEO ownership	0.3%
Management average tenure	5.8yrs
Board average tenure	9.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Curt Hartman's remuneration changed compared to CONMED's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	US$132m
Jun 30 2024	n/a	n/a	US$99m
Mar 31 2024	n/a	n/a	US$82m
Dec 31 2023	US$8m	US$950k	US$64m
Sep 30 2023	n/a	n/a	US$58m
Jun 30 2023	n/a	n/a	US$88m
Mar 31 2023	n/a	n/a	-US$94m
Dec 31 2022	US$8m	US$946k	-US$81m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	US$68m
Dec 31 2021	US$9m	US$918k	US$63m
Sep 30 2021	n/a	n/a	US$62m
Jun 30 2021	n/a	n/a	US$54m
Mar 31 2021	n/a	n/a	US$13m
Dec 31 2020	US$6m	US$888k	US$10m
Sep 30 2020	n/a	n/a	US$311k
Jun 30 2020	n/a	n/a	US$431k
Mar 31 2020	n/a	n/a	US$34m
Dec 31 2019	US$6m	US$842k	US$29m
Sep 30 2019	n/a	n/a	US$29m
Jun 30 2019	n/a	n/a	US$28m
Mar 31 2019	n/a	n/a	US$31m
Dec 31 2018	US$5m	US$791k	US$41m
Sep 30 2018	n/a	n/a	US$72m
Jun 30 2018	n/a	n/a	US$73m
Mar 31 2018	n/a	n/a	US$71m
Dec 31 2017	US$3m	US$753k	US$55m

Compensation vs Market: Curt's total compensation ($USD7.76M) is above average for companies of similar size in the MX market ($USD704.37K).

Compensation vs Earnings: Curt's compensation has been consistent with company performance over the past year.

CEO

Curt Hartman (60 yo)

10.3yrs

Tenure

US$7,764,615

Compensation

Mr. Curt R. Hartman serves as the Director of CONMED Corporation since October 31, 2024 and Chief Executive Officer and President of CONMED Corporation since November 09, 2014, He served as Chairman of the...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Curt Hartman	President	10.3yrs	US$7.76m	0.30% MX$ 135.6m
Todd Garner	Executive VP	6.8yrs	US$2.87m	0.00073% MX$ 327.0k
Patrick Beyer	Chief Operating Officer	less than a year	US$3.30m	0.035% MX$ 15.7m
Richard Glaze	Chief Information Officer	no data	no data	no data
Hollie Foust	General Counsel & Corporate Secretary	no data	no data	no data
Peter Shagory	Executive Vice President of Strategy & Corporate Development	9.5yrs	no data	0.012% MX$ 5.4m
Shanna Cotti-Osmanski	Executive VP of Information Technology & CIO	4.7yrs	no data	no data
John Ferrell	Executive Vice President of Human Resources	1.9yrs	no data	0.0023% MX$ 1.0m
David Murray	President of ConMed Electrosurgery	20.3yrs	US$572.33k	no data
Johonna Pelletier	VP of Tax & Treasurer	9.6yrs	no data	0.0043% MX$ 1.9m
Kimberly Lockwood	Interim Corporate Controller	less than a year	no data	no data

5.8yrs

Average Tenure

56yo

Average Age

Experienced Management: CNMD *'s management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Curt Hartman	President	10.7yrs	US$7.76m	0.30% MX$ 135.6m
John Workman	Independent Director	9.3yrs	US$257.37k	0.066% MX$ 29.6m
David Bronson	Independent Director	9.3yrs	US$264.87k	0.054% MX$ 24.3m
Brian Concannon	Independent Director	11.3yrs	US$257.37k	0.031% MX$ 14.0m
LaVerne Council	Independent Director	4.9yrs	US$257.37k	0.012% MX$ 5.2m
Martha Aronson	Independent Chair of the Board	8.8yrs	US$292.37k	0.045% MX$ 20.2m
Charles Farkas	Independent Director	10.3yrs	US$249.87k	0.066% MX$ 29.5m
Barbara Schwarzentraub	Independent Director	5.2yrs	US$264.87k	0.017% MX$ 7.7m

9.3yrs

Average Tenure

64yo

Average Age

Experienced Board: CNMD *'s board of directors are considered experienced (9.3 years average tenure).

CONMED Management

Management criteria checks 3/4

Key information

Recent management updates

CONMED Corporation Announces Chief Executive Officer Changes

Insufficient new directors

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

Insufficient new directors

Chief Operating Officer recently bought Mex$3.5m worth of stock

Insufficient new directors

Recent updates

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation to Report Q3, 2024 Results on Oct 30, 2024

Upcoming dividend of US$0.20 per share

Insufficient new directors

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

Second quarter 2024 earnings released: EPS: US$0.97 (vs US$0.45 in 2Q 2023)

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

Insufficient new directors

CONMED Corporation to Report Q2, 2024 Results on Jul 31, 2024

Upcoming dividend of US$0.20 per share

First quarter dividend of US$0.20 announced

CONMED Corporation Declares Quarterly Cash Dividend, Payable on July 5, 2024

Chief Operating Officer recently bought Mex$3.5m worth of stock

Insufficient new directors

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

Insufficient new directors

CONMED Corporation, Annual General Meeting, May 22, 2024

CONMED Corporation, Annual General Meeting, May 22, 2024

CONMED Corporation to Report Q1, 2024 Results on Apr 24, 2024

CONMED Corporation Declares Quarterly Cash Dividend, Payable on April 5, 2024

CONMED Corporation Provides Financial Guidance for the Full Year 2024

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2024

Insufficient new directors

CONMED Corporation Updates Third Quarter Guidance for 2023

Insufficient new directors

CONMED Corporation to Report Q3, 2023 Results on Oct 25, 2023

Insufficient new directors

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2023

Second quarter 2023 earnings released: EPS: US$0.45 (vs US$5.65 loss in 2Q 2022)

CONMED Corporation Revises Earnings Guidance for the Full Year 2023

Insufficient new directors

CONMED Corporation to Report Q2, 2023 Results on Jul 26, 2023

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2023

Insufficient new directors

Insufficient new directors

Full year 2022 earnings released: US$2.68 loss per share (vs US$2.15 profit in FY 2021)

CONMED Corporation Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

CONMED Corporation to Report Q4, 2022 Results on Feb 02, 2023

CONMED Corporation Announces Management Changes

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2023

Insufficient new directors

CONMED Corporation Provides Revenue Guidance for the Full Year 2023

Insufficient new directors

Now 24% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$1.51 (vs US$0.51 in 3Q 2021)

CONMED Corporation Revises Earnings Guidance for the Full Year 2022

Now 21% undervalued

CONMED Corporation to Report Q3, 2022 Results on Oct 26, 2022

Insufficient new directors

Chairman of the Board recently sold Mex$6.6m worth of stock

Now 21% undervalued after recent price drop

Upcoming dividend of US$0.20 per share

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2022

CONMED Corporation (NYSE:CNMD) completed the acquisition of Biorez, Inc.

CONMED Corporation (NYSE:CNMD) completed the acquisition of Biorez, Inc.

CONMED Corporation (NYSE:CNMD) has entered into a definitive agreement to acquire Biorez, Inc. for $250 million.

CONMED Corporation (NYSE:CNMD) has entered into a definitive agreement to acquire Biorez, Inc. for $250 million.

Second quarter 2022 earnings released: US$5.65 loss per share (vs US$0.46 profit in 2Q 2021)

CONMED Corporation Revises Earnings Guidance for the Full Year 2022

CONMED Corporation to Report Q2, 2022 Results on Jul 27, 2022

CONMED Corporation(NYSE:CNMD) dropped from Russell 2000 Dynamic Index

Now 20% undervalued

CONMED Corporation (NYSE:CNMD) completed the acquisition of In2Bones Global, Inc.

Upcoming dividend of US$0.20 per share

CEO Compensation Analysis

CEO

Tenure